As per Fact.MR – a market research and competitive intelligence provider, the global chemotherapy-induced nausea and vomiting (CINV) treatment market is valued at US$ 5.7 Bn in 2021, and is expected to exhibit a CAGR of around 6% over the forecast period (2021-2031). As medical expenditure for chemotherapy and number of cancer cases continue to rise, treatment of chemotherapy-induced nausea and vomiting becomes more essential to reduce the financial burden on the healthcare system as well as patients. Thus, key market players are continuously involved in developing advanced treatment options for chemotherapy-induced nausea and vomiting.
For instance, in June 2021, Tetra Bio-Pharma Inc. received Health Canada acceptance for its New Drug Submission (NDS) for REDUVO as a treatment for patients with CINV.
Similarly, increasing compliance to chemotherapy drugs due to varied treatment options and availability of combination therapies have increased the adoption of chemotherapy-induced nausea and vomiting treatment. The current COVID-19 pandemic crisis is expected to have a moderately negative impact on market growth. The crisis led to the shutdown of several manufacturing units, leading to supply chain disruptions, which resulted in delay of CINV treatment.
For more insights into the Market, Request a Sample of this Report –https://www.factmr.com/connectus/sample?flag=S&rep_id=6867
Key Takeaways from Market Study
- By form, injectables hold around 66% value share of the global market.
- Based on drug class, 5-HT3 receptor antagonists are leading with 42% market share.
- Based on emetogenic risk, the highly emetogenic chemotherapy (HEC) segment holds a high share of 63%.
- By distribution channel, hospitals dominate the market with a value share of 36%, while on the other hand, cancer research institutes are expected to rise at a higher CAGR of 4.5%.
- By region, North America dominates the global chemotherapy-induced nausea and vomiting treatment market with a value share of 44%.
“Growing incidence of cancer and surge in patients undergoing chemotherapy treatments and availability of combination therapies are anticipated to drive market growth over the coming years,” says a Fact.MR analyst.
What are the Key Opportunities for CINV Treatment Product Manufacturers?
There are several approved drugs available in the market for the treatment of chemotherapy-induced nausea and vomiting. The types of approved medications used to treat CINV include 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, and cannabinoids.
Most patients adopt these drugs for managing chemotherapy-induced nausea and vomiting, manufactured by Kyowa Kirin, Inc., Pfizer Inc., and Merck & Co., Inc. among others. These pharmaceutical companies have a global presence, which enables them to promote and distribute their drugs throughout the globe. Moreover, many branded drugs are easily available in the market for chemotherapy-induced nausea and vomiting corticosteroids therapy.
It has been estimated that pharmaceutical companies invest around 10% of their total turnover in new R&D initiatives, while the cost of R&D has increased by over 150% over the past decade. Hence, identification of new drug combinations beforehand is vital.
Manufacturers are also trying to develop generic competencies to validate bioequivalence to reference prescription drugs in the CINV market, as several key drugs no longer benefit from intellectual property protection.
Availability of a large number of approved drugs for the treatment of chemotherapy-induced nausea and vomiting in retail pharmacies and high investments in R&D by pharmaceuticals companies have created tremendous opportunities for the growth of the market.
How Lucrative is the Opportunity for CINV Drug Manufacturers in the U.S.?
The U.S. is estimated to account for nearly 86% share in 2021 and represents the largest regional market in the world. Leading pharmaceutical companies in the country are focusing on the development of oral chemotherapy-induced nausea and vomiting treatment drugs and intravenous CINV treatment drugs for treatment.
Moreover, few manufacturers are solely focusing on the development of drugs for the treatment of CINV with minimum side-effects. Besides, several new and improved drugs for chemotherapy are been launched in the market.
For instance, in August 2016, Heron Therapeutics received U.S. FDA approval for SUSTOL, an extended-release injection of granisetron for the prevention of CINV.
In October 2017, TESARO Inc. received U.S. FDA approval of VARUBI IV for delayed CINV.
Thus, increasing spending by leading pharmaceutical companies for product launch and development of drugs for treatment of chemotherapy-induced nausea in cancer patients is driving the U.S. chemotherapy-induced nausea and vomiting therapeutics market.
Request Methodology & Get a Glimpse of Our Expertise –https://www.factmr.com/connectus/sample?flag=RM&rep_id=6867
Competitive Landscape
The global CINV treatment market is marked by the presence of emerging as well as established players. Rising need for chemotherapy-induced nausea and vomiting treatment has motivated key players to launch new and innovative products in the market.
Leading manufacturers of medications for the treatment of chemotherapy-induced nausea and vomiting are focusing on acquisitions to expand their product portfolios and gain maximum market share.
- In January 2019, GSK completed the acquisition of TESARO Inc., an oncology-focused biopharmaceutical company, for an aggregate cash consideration of approximately US$ 5.1 billion.
- In July 2019, Pfizer Inc. acquired U.S.-based pharmaceutical company Array BioPharma Inc. This acquisition is estimated to strengthen the innovative biopharmaceutical business and assist in meeting the unmet medical needs of diseases such as cancer and other rare diseases.
Segments as per Global CINV Treatment Industry Research
By Form
- Injectables
- Oral
- Transdermal Patches
By Drug Class
- 5-HT3 Receptor Antagonists
- Neurokinin-1 Receptor Antagonists
- Corticosteroids
- Cannabinoids
- Others
By Emetogenik Risk
- Highly Emetogenic Chemotherapy (HEC)
- Moderately Emetogenic Chemotherapy (MEC)
- Low Emetogenic Chemotherapy (LEC)
By Distribution Channel
- CINV Hospitals
- Cancer Research Institute
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
Key Analysis Offered in Chemotherapy-Induced Nausea and Vomiting Treatment Industry Survey
- Market Estimates and Forecasts 2016-2031
- Key Drivers and Restraints Impacting Market Growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competition Mapping and Benchmarking
- Market Share Analysis by Key Players
- Key Product Innovations and Regulatory Scenario
- COVID-19 Impact on Demand for Chemotherapy Induced Nausea and Vomiting Treatment and How to Navigate
- Recommendation on Key Winning Strategies
Choose Quick and Secure PayPal Payment Mode to Get Full Access of This Reporthttps://www.factmr.com/checkout/6867
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Email: [email protected]